Vanguard Group Inc Immuno Gen, Inc. Transaction History

Vanguard Group Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$12.46 - $29.95 $12.3 Million - $29.5 Million	984,795 Added 4.02%	25,466,950 $755 Million
Q3 2023 Nov 14, 2023	BUY	$14.09 - $19.87 $50.5 Million - $71.2 Million	3,583,129 Added 17.14%	24,482,155 $389 Million
Q2 2023 Aug 14, 2023	BUY	$3.75 - $20.05 $22.2 Million - $119 Million	5,930,704 Added 39.62%	20,899,026 $394 Million
Q1 2023 May 15, 2023	BUY	$3.67 - $4.92 $2.16 Million - $2.9 Million	589,887 Added 4.1%	14,968,322 $57.5 Million
Q4 2022 Feb 10, 2023	SELL	$4.55 - $6.31 $5.67 Million - $7.86 Million	-1,246,413 Reduced 7.98%	14,378,435 $71.3 Million

Q3 2022 Nov 14, 2022	SELL	$4.48 - $6.47 $1.95 Million - $2.81 Million	-434,172 Reduced 2.7%	15,624,848 $74.7 Million
Q2 2022 Aug 12, 2022	BUY	$3.15 - $5.76 $1.83 Million - $3.34 Million	580,504 Added 3.75%	16,059,020 $72.3 Million
Q1 2022 May 13, 2022	BUY	$4.26 - $7.48 $1.48 Million - $2.59 Million	346,764 Added 2.29%	15,478,516 $73.7 Million
Q4 2021 Feb 14, 2022	BUY	$4.75 - $7.5 $2.47 Million - $3.9 Million	520,129 Added 3.56%	15,131,752 $112 Million
Q3 2021 Nov 12, 2021	SELL	$5.02 - $6.59 $208,666 - $273,926	-41,567 Reduced 0.28%	14,611,623 $82.8 Million
Q2 2021 Aug 13, 2021	BUY	$5.79 - $8.6 $84.8 Million - $126 Million	14,653,190 New	14,653,190 $96.6 Million

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.